ADHD Treatments Under the Spotlight: Weighing Benefits and Harms
November 28, 2025
Brand Name :
N/A
Synonyms :
dapivirine intravaginal
Class :
HIV, Non-nucleoside reverse transcriptase inhibitor (NNRTIs)
Monthly once vaginal ring but FDA approval pending for prevention of human immune virus infection
Not suggested yetÂ
Refer to adult dosingÂ
Actions and Spectrum Â
The reverse transcriptase enzyme, which is necessary for HIV replication, is inhibited by dapivirine intravaginal. It prevents the virus from turning its RNA into DNA by inhibiting this enzyme. Â
The most prevalent type of the virus that causes the worldwide HIV epidemic, HIV-1, is specifically susceptible to the action of the drug dapivirine.Â
None
Black Box Warning:Â
NoneÂ
Contraindication/Caution:Â Â Â
None
Pregnancy warnings:    Â
Pregnancy category: N/AÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category.
Pharmacology Â
dapivirine intravaginal belongs to the class of non-nucleoside reverse transcriptase inhibitors (NNRTIs). It inhibits the reverse transcriptase enzyme of the human immunodeficiency virus type 1 (HIV-1).Â
PharmacodynamicsÂ
Limited information available Â
PharmacokineticsÂ
Limited information available on ADMEÂ Â
Administration Â
dapivirine intravaginal is administered using a specifically designed intravaginal ring (IVR).
Patient information leafletÂ
Generic Name: dapivirine intravaginal (FDA Approval Pending)Â
Why do we use dapivirine intravaginal?Â
dapivirine intravaginal is used as a form of pre-exposure prophylaxis to reduce the risk of HIV-1 infection in women.Â